Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

Tineke Casneuf1 Homer C. Adams III2 Niels W.C.J. van de Donk3 Yann Abraham1 Jaime Bald2 Greet Vanhoof1 Koen Van der Borght1 Tina Smets1 Brad Foulk2 Karl C. Nielsen2 Joshua Rusbuldt2 Amy Axel2 Andrew Lysaght4 Hugo Ceulemans1 Frederik Stevenaert1 Saad Z. Usmani5 Torben Plesner6 Herve Avet-Loiseau7 Inger Nijhof3 Tuna Mutis3 Jordan M. Schecter8 Christopher Chiu2 Nizar J. Bahlis9 1 Janssen Research & Development, Beerse, Belgium 2 Janssen Research & Development, LLC, Spring House, PA, USA Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands 3 Vejle Hospital and University of Southern Denmark, 4 Immuneering Corp, Cambridge, MA, USA 5 Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA 6 Vejle, Denmark 7 Toulouse, France 8 9 Janssen Research & Development, LLC, Raritan, NJ, USA Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada